Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Prostate Cancer

Free Subscription Articles published in Radiology Retrieve available abstracts of 66 articles: HTML format

Single Articles

July 2024
1. GHAI S, Klotz L, Pond GR, Kebabdjian M, et al
   Comparison of Multiparametric MRI-targeted and Systematic Biopsies for Detection of Cribriform and Intraductal Carcinoma Prostate Cancer.
   Radiology. 2024;312:e231948.
   PubMed     Abstract available
   
   
   
2. SCIALPI M, Martorana E
   Apparent Diffusion Coefficient and Biopsy in Detecting Cribriform and Intraductal Carcinoma Prostate Cancer.
   Radiology. 2024;312:e241043.
   PubMed    
   
   
   June 2024
3. SCHIEDA N, Nisha Y, Hadziomerovic AR, Prabhakar S, et al
   Comparison of Positive Predictive Values of Biparametric MRI and Multiparametric MRI-directed Transrectal US-guided Targeted Prostate Biopsy.
   Radiology. 2024;311:e231383.
   PubMed     Abstract available
   
   
   
4. JEWELL K, Hofman MS, Ong JSL, Levy S, et al
   Erratum for: Emerging Theranostics for Prostate Cancer and a Model of Prostate-specific Membrane Antigen Therapy.
   Radiology. 2024;311:e249017.
   PubMed    
   
   
   May 2024
5. LIN Y, Yilmaz EC, Belue MJ, Harmon SA, et al
   Evaluation of a Cascaded Deep Learning-based Algorithm for Prostate Lesion Detection at Biparametric MRI.
   Radiology. 2024;311:e230750.
   PubMed     Abstract available
   
   
   
6. PRIVE BM, Israel B, Janssen MJR, van der Leest MMG, et al
   Multiparametric MRI and (18)F-PSMA-1007 PET/CT for the Detection of Clinically Significant Prostate Cancer.
   Radiology. 2024;311:e231879.
   PubMed     Abstract available
   
   
   April 2024
7. JEWELL K, Hofman MS, Ong JSL, Levy S, et al
   Emerging Theranostics for Prostate Cancer and a Model of Prostate-specific Membrane Antigen Therapy.
   Radiology. 2024;311:e231703.
   PubMed     Abstract available
   
   
   March 2024
8. WOODRUM DA
   Less Is More: MRI-guided Focused Ultrasound Focal Therapy for Intermediate-Risk Prostate Cancer.
   Radiology. 2024;310:e240258.
   PubMed    
   
   
   
9. GHAI S, Finelli A, Corr K, Lajkosz K, et al
   MRI-guided Focused Ultrasound Focal Therapy for Intermediate-Risk Prostate Cancer: Final Results from a 2-year Phase II Clinical Trial.
   Radiology. 2024;310:e231473.
   PubMed     Abstract available
   
   
   December 2023
10. MURAD V, Glicksman RM, Berlin A, Santiago A, et al
    Association of PSMA PET-derived Parameters and Outcomes of Patients Treated for Oligorecurrent Prostate Cancer.
    Radiology. 2023;309:e231407.
    PubMed     Abstract available
    
    
    
11. ALABOUSI M, Ghai S, Haider MA
    MRI-guided Minimally Invasive Focal Therapies for Prostate Cancer.
    Radiology. 2023;309:e230431.
    PubMed     Abstract available
    
    
    
12. CIVELEK AC
    PSMA PET Parameters for Predicting Outcomes in Patients with Prostate Cancer.
    Radiology. 2023;309:e233023.
    PubMed    
    
    
    November 2023
13. TAKAHASHI T
    Prebiopsy Risk Calculators, Such as MRI and Prostate Cancer Screening, Are Early-phase Clinical Trials.
    Radiology. 2023;309:e231177.
    PubMed    
    
    
    
14. AGUIRRE DA, Cardona Ortegon JD
    Unlocking the Benefits of Multiparametric MRI for Predicting Prostate Cancer Recurrence.
    Radiology. 2023;309:e232819.
    PubMed    
    
    
    
15. LUZZAGO S, Colombo A, Mistretta FA, Alessi S, et al
    Multiparametric MRI-based 5-year Risk Prediction Model for Biochemical Recurrence of Prostate Cancer after Radical Prostatectomy.
    Radiology. 2023;309:e223349.
    PubMed     Abstract available
    
    
    September 2023
16. BISCHOFF LM, Peeters JM, Weinhold L, Krausewitz P, et al
    Deep Learning Super-Resolution Reconstruction for Fast and Motion-Robust T2-weighted Prostate MRI.
    Radiology. 2023;308:e230427.
    PubMed     Abstract available
    
    
    July 2023
17. GAFITA A, Djaileb L, Rauscher I, Fendler WP, et al
    Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in Metastatic Castration-resistant Prostate Cancer.
    Radiology. 2023;308:e222148.
    PubMed     Abstract available
    
    
    
18. WEI C, Szewczyk-Bieda M, Bates AS, Donnan PT, et al
    Multicenter Randomized Trial Assessing MRI and Image-guided Biopsy for Suspected Prostate Cancer: The MULTIPROS Study.
    Radiology. 2023;308:e221428.
    PubMed     Abstract available
    
    
    June 2023
19. PADHANI AR, Schoots IG
    Imaging-based Diagnostic and Therapeutic Strategies for Prostate Cancer in the Coming Decades.
    Radiology. 2023;307:e222990.
    PubMed    
    
    
    
20. TURKBEY B, Purysko AS
    PI-RADS: Where Next?
    Radiology. 2023;307:e223128.
    PubMed     Abstract available
    
    
    May 2023
21. YILMAZ EC, Shih JH, Belue MJ, Harmon SA, et al
    Prospective Evaluation of PI-RADS Version 2.1 for Prostate Cancer Detection and Investigation of Multiparametric MRI-derived Markers.
    Radiology. 2023 May 2:221309. doi: 10.1148/radiol.221309.
    PubMed     Abstract available
    
    
    
22. GOH V
    PI-RADS and Multiparametric MRI: The Shape of Things to Come for Prostate Cancer.
    Radiology. 2023 May 2:230643. doi: 10.1148/radiol.230643.
    PubMed    
    
    
    April 2023
23. SEIFERT R, Rasul S, Seitzer K, Eveslage M, et al
    A Prognostic Risk Score for Prostate Cancer Based on PSMA PET-derived Organ-specific Tumor Volumes.
    Radiology. 2023 Apr 18:222010. doi: 10.1148/radiol.222010.
    PubMed     Abstract available
    
    
    
24. CIVELEK AC
    Reawakening of Nuclear Medicine through Molecular Imaging: Quantitative Theranostics and PSMA PET.
    Radiology. 2023 Apr 18:230627. doi: 10.1148/radiol.230627.
    PubMed    
    
    
    
25. HAMM CA, Baumgartner GL, Biessmann F, Beetz NL, et al
    Interactive Explainable Deep Learning Model Informs Prostate Cancer Diagnosis at MRI.
    Radiology. 2023 Apr 11:222276. doi: 10.1148/radiol.222276.
    PubMed     Abstract available
    
    
    
26. CHAPIRO J
    Explainable AI for Prostate MRI: Don't Trust, Verify.
    Radiology. 2023 Apr 11:230574. doi: 10.1148/radiol.230574.
    PubMed    
    
    
    February 2023
27. SCIALPI M, Martorana E, Scalera GB, Scialpi P, et al
    Apparent Diffusion Coefficient and Lesion Volume to Detect Prostate Cancer.
    Radiology. 2023 Feb 28:222177. doi: 10.1148/radiol.222177.
    PubMed    
    
    
    December 2022
28. STAVRINIDES V, Norris JM, Karapanagiotis S, Giganti F, et al
    Regional Histopathology and Prostate MRI Positivity: A Secondary Analysis of the PROMIS Trial.
    Radiology. 2022 Dec 13:220762. doi: 10.1148/radiol.220762.
    PubMed     Abstract available
    
    
    September 2022
29. PARIHAR AS, Hofman MS, Iravani A
    (177)Lu-Prostate-specific Membrane Antigen Radioligand Therapy in Patients with Metastatic Castration-resistant Prostate Cancer.
    Radiology. 2022 Sep 20:220859. doi: 10.1148/radiol.220859.
    PubMed     Abstract available
    
    
    August 2022
30. GOH V
    Tumor Physiology and Clinically Significant Prostate Cancer Detection.
    Radiology. 2022 Aug 16:221798. doi: 10.1148/radiol.221798.
    PubMed    
    
    
    
31. TAVAKOLI AA, Hielscher T, Badura P, Gortz M, et al
    Contribution of Dynamic Contrast-enhanced and Diffusion MRI to PI-RADS for Detecting Clinically Significant Prostate Cancer.
    Radiology. 2022 Aug 16:212692. doi: 10.1148/radiol.212692.
    PubMed     Abstract available
    
    
    
32. SINGH S, Rogers H, Kanber B, Clemente J, et al
    Avoiding Unnecessary Biopsy after Multiparametric Prostate MRI with VERDICT Analysis: The INNOVATE Study.
    Radiology. 2022 Aug 2:212536. doi: 10.1148/radiol.212536.
    PubMed     Abstract available
    
    
    July 2022
33. LEE GH, Chatterjee A, Karademir I, Engelmann R, et al
    Comparing Radiologist Performance in Diagnosing Clinically Significant Prostate Cancer with Multiparametric versus Hybrid Multidimensional MRI.
    Radiology. 2022 Jul 26:211895. doi: 10.1148/radiol.211895.
    PubMed     Abstract available
    
    
    
34. TURKBEY B
    Hybrid Multidimensional Prostate MRI: A Quantitative Step in the Right Direction.
    Radiology. 2022 Jul 26:221452. doi: 10.1148/radiol.221452.
    PubMed    
    
    
    
35. ZUKOTYNSKI KA, Kuo PH
    (18)F-DCFPyL PET/CT in Men with Prostate Cancer.
    Radiology. 2022 Jul 19:221536. doi: 10.1148/radiol.221536.
    PubMed    
    
    
    
36. ULANER GA, Thomsen B, Bassett J, Torrey R, et al
    (18)F-DCFPyL PET/CT for Initially Diagnosed and Biochemically Recurrent Prostate Cancer: Prospective Trial with Pathologic Confirmation.
    Radiology. 2022 Jul 19:220218. doi: 10.1148/radiol.220218.
    PubMed     Abstract available
    
    
    
37. GHAI S, Perlis N, Atallah C, Jokhu S, et al
    Comparison of Micro-US and Multiparametric MRI for Prostate Cancer Detection in Biopsy-Naive Men.
    Radiology. 2022 Jul 19:212163. doi: 10.1148/radiol.212163.
    PubMed     Abstract available
    
    
    May 2022
38. JADVAR H
    Prostate-specific Membrane Antigen PET: Standard Imaging in Prostate Cancer.
    Radiology. 2022 May 24:221074. doi: 10.1148/radiol.221074.
    PubMed    
    
    
    
39. BASSO DIAS A, Finelli A, Bauman G, Veit-Haibach P, et al
    Impact of (18)F-DCFPyL PET on Staging and Treatment of Unfavorable Intermediate or High-Risk Prostate Cancer.
    Radiology. 2022 May 24:211836. doi: 10.1148/radiol.211836.
    PubMed     Abstract available
    
    
    
40. HAIDER MA
    It's Time for a Standardized MRI Assessment Scheme for Prostate Cancer Recurrence.
    Radiology. 2022 May 10:220701. doi: 10.1148/radiol.220701.
    PubMed    
    
    
    
41. PECORARO M, Turkbey BI, Purysko AS, Girometti R, et al
    Diagnostic Accuracy and Observer Agreement of the MRI Prostate Imaging for Recurrence Reporting Assessment Score.
    Radiology. 2022 May 10:212252. doi: 10.1148/radiol.212252.
    PubMed     Abstract available
    
    
    March 2022
42. WU D, Jiang K, Li H, Zhang Z, et al
    Time-Dependent Diffusion MRI for Quantitative Microstructural Mapping of Prostate Cancer.
    Radiology. 2022 Mar 8:211180. doi: 10.1148/radiol.211180.
    PubMed     Abstract available
    
    
    
43. CHATTERJEE A, Oto A
    Prostate Tissue Microstructural Estimates Using Time-Dependent Diffusion MRI.
    Radiology. 2022 Mar 8:220056. doi: 10.1148/radiol.220056.
    PubMed    
    
    
    February 2022
44. KUMAR R, Singh SK, Mittal BR, Vadi SK, et al
    Safety and Diagnostic Yield of (68)Ga Prostate-specific Membrane Antigen PET/CT Guided Robotic-assisted Transgluteal Prostatic Biopsy.
    Radiology. 2022 Feb 22:204066. doi: 10.1148/radiol.204066.
    PubMed     Abstract available
    
    
    
45. UEDA T, Ohno Y, Yamamoto K, Murayama K, et al
    Deep Learning Reconstruction of Diffusion-weighted MRI Improves Image Quality for Prostatic Imaging.
    Radiology. 2022 Feb 1:204097. doi: 10.1148/radiol.204097.
    PubMed     Abstract available
    
    
    January 2022
46. CIVELEK AC
    Management of Metastatic Prostate Cancer Biochemical Recurrence with Use of (18)F-DCFPyL PET/CT.
    Radiology. 2022 Jan 25:212993. doi: 10.1148/radiol.212993.
    PubMed    
    
    
    
47. METSER U, Zukotynski K, Mak V, Langer D, et al
    Effect of (18)F-DCFPyL PET/CT on the Management of Patients with Recurrent Prostate Cancer: Results of a Prospective Multicenter Registry Trial.
    Radiology. 2022 Jan 25:211824. doi: 10.1148/radiol.211824.
    PubMed     Abstract available
    
    
    
48. RANASINGHE WKB, Troncoso P, Surasi DS, Ibarra Rovira JJ, et al
    Defining Diagnostic Criteria for Prostatic Ductal Adenocarcinoma at Multiparametric MRI.
    Radiology. 2022 Jan 25:204732. doi: 10.1148/radiol.204732.
    PubMed     Abstract available
    
    
    
49. LAMBERG H, Shankar PR, Singh K, Caoili EM, et al
    Preoperative Prostate MRI Predictors of Urinary Continence Following Radical Prostatectomy.
    Radiology. 2022 Jan 18:210500. doi: 10.1148/radiol.210500.
    PubMed     Abstract available
    
    
    
50. KANAS AF, Fenelon SS, Santos JMMM, Coelho RF, et al
    Case 297: Mucinous Adenocarcinoma of the Prostate.
    Radiology. 2022;302:238-242.
    PubMed     Abstract available
    
    
    December 2021
51. GOTTLIEB RH
    Introducing a Standard in Prostate Cancer Imaging Evaluation.
    Radiology. 2021 Dec 21:212111. doi: 10.1148/radiol.212111.
    PubMed    
    
    
    
52. WIBMER AG, Nikolovski I, Chaim J, Lakhman Y, et al
    Local Extent of Prostate Cancer at MRI versus Prostatectomy Histopathology: Associations with Long-term Oncologic Outcomes.
    Radiology. 2021 Dec 21:210875. doi: 10.1148/radiol.210875.
    PubMed     Abstract available
    
    
    November 2021
53. CHATTERJEE A, Mercado C, Bourne RM, Yousuf A, et al
    Validation of Prostate Tissue Composition by Using Hybrid Multidimensional MRI: Correlation with Histologic Findings.
    Radiology. 2021 Nov 9:204459. doi: 10.1148/radiol.2021204459.
    PubMed     Abstract available
    
    
    
54. WILLIAMS HT, Estes TL
    Anatomic and Functional Prostate Cancer Imaging.
    Radiology. 2021;301:E418.
    PubMed    
    
    
    October 2021
55. KANG SK, Mali RD, Prabhu V, Ferket BS, et al
    Active Surveillance Strategies for Low-Grade Prostate Cancer: Comparative Benefits and Cost-effectiveness.
    Radiology. 2021;301:E380.
    PubMed    
    
    
    August 2021
56. WILLIAMS HT, Estes TL
    Anatomic and Functional Prostate Cancer Imaging.
    Radiology. 2021 Aug 31:211837. doi: 10.1148/radiol.2021211837.
    PubMed    
    
    
    
57. MARGEL D, Bernstine H, Groshar D, Ber Y, et al
    Diagnostic Performance of (68)Ga Prostate-specific Membrane Antigen PET/MRI Compared with Multiparametric MRI for Detecting Clinically Significant Prostate Cancer.
    Radiology. 2021 Aug 31:204093. doi: 10.1148/radiol.2021204093.
    PubMed     Abstract available
    
    
    July 2021
58. KANG SK, Mali RD, Prabhu V, Ferket BS, et al
    Active Surveillance Strategies for Low-Grade Prostate Cancer: Comparative Benefits and Cost-effectiveness.
    Radiology. 2021 Jul 13:204321. doi: 10.1148/radiol.2021204321.
    PubMed     Abstract available
    
    
    May 2021
59. DENIFFEL D, Healy GM, Dong X, Ghai S, et al
    Avoiding Unnecessary Biopsy: MRI-based Risk Models versus a PI-RADS and PSA Density Strategy for Clinically Significant Prostate Cancer.
    Radiology. 2021 May 25:204112. doi: 10.1148/radiol.2021204112.
    PubMed     Abstract available
    
    
    
60. LI M, Guo J, Hu P, Jiang H, et al
    Tomoelastography Based on Multifrequency MR Elastography for Prostate Cancer Detection: Comparison with Multiparametric MRI.
    Radiology. 2021;299:E259.
    PubMed    
    
    
    
61. GHAI S, Finelli A, Corr K, Chan R, et al
    MRI-guided Focused Ultrasound Ablation for Localized Intermediate-Risk Prostate Cancer: Early Results of a Phase II Trial.
    Radiology. 2021;299:E258.
    PubMed    
    
    
    
62. GOLDBERG SN
    More Interventional Oncologic Fire from COLDFIRE-2.
    Radiology. 2021;299:481-482.
    PubMed    
    
    
    April 2021
63. HARMON SA, Gesztes W, Young D, Mehralivand S, et al
    Prognostic Features of Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy Based on Multiparametric MRI and Immunohistochemistry Analysis of MRI-guided Biopsy Specimens.
    Radiology. 2021 Apr 13:202425. doi: 10.1148/radiol.2021202425.
    PubMed     Abstract available
    
    
    
64. COSTA DN
    Multiparametric MRI of the Prostate: Beyond Cancer Detection and Staging.
    Radiology. 2021 Apr 13:204506. doi: 10.1148/radiol.2021204506.
    PubMed    
    
    
    February 2021
65. TEMPANY-AFDHAL CMC, Padhani A, Barentsz J, Weinreb J, et al
    Perspectives and Concerns about PI-RADS and Variability.
    Radiology. 2021;298:E112.
    PubMed    
    
    
    November 2020
66. BAZARGANI S, Bandyk M, Balaji KC
    Variability of the Positive Predictive Value of PI-RADS for Prostate MRI across 26 Centers: What about the Negatives?
    Radiology. 2020 Nov 3:202870. doi: 10.1148/radiol.2020202870.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.